


L15 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:12444 CAPLUS <<LOGINID::20080617>>
 DOCUMENT NUMBER: 134:86248
 TITLE: Preparation of benzimidazoles as respiratory syncytial virus replication inhibitors.
 INVENTOR(S): Janssens, Frans Eduard; Meersman, Kathleen Petrus Marie-Jose; Sommen, Francois Maria; Guillemont, Jerome Emile Georges; Lacrampe, Jean Fernand Armand; Andries, Koenraad Jozef Lodewijk Marcel
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
 SOURCE: PCT Int. Appl., 119 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000611	A1	20010104	WO 2000-EP5676	20000620
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2376781	A1	20010104	CA 2000-2376781	20000620
BR 2000012054	A	20020319	BR 2000-12054	20000620
EP 1196408	A1	20020417	EP 2000-943841	20000620
EP 1196408	B1	20040915		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200103804	T2	20020521	TR 2001-3804	20000620
HU 2002001723	A2	20021128	HU 2002-1723	20000620
HU 2002001723	A3	20040428		
JP 2003503401	T	20030128	JP 2001-507020	20000620
EE 200100692	A	20030217	EE 2001-692	20000620
EE 4590	B1	20060215		
NZ 515418	A	20031128	NZ 2000-515418	20000620
EP 1418175	A1	20040512	EP 2004-100543	20000620
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, LT, LV, FI, MK, CY, AL				
AT 276244	T	20041015	AT 2000-943841	20000620
AU 779516	B2	20050127	AU 2000-58167	20000620
PT 1196408	T	20050131	PT 2000-943841	20000620
ES 2228559	T3	20050416	ES 2000-943841	20000620
AP 1552	A	20060228	AP 2002-2397	20000620
W: GM, GH, KE, LS, MW, MZ, SL, SD, SZ, TZ, UG, ZM, ZW				
SG 122814	A1	20060629	SG 2004-362	20000620
TR 200600172	T1	20070122	TR 2006-172	20000620
TW 248932	B	20060211	TW 2000-89112477	20000626

IN 2001MN01539	A	20050304	IN 2001-MN1539	20011206
MX 2002PA00112	A	20020702	MX 2002-PA112	20011219
HR 2001000933	A1	20030630	HR 2001-933	20011219
ZA 2001010478	A	20030320	ZA 2001-10478	20011220
NO 2001006368	A	20020228	NO 2001-6368	20011227
NO 324036	B1	20070730		
US 6924287	B1	20050802	US 2001-30202	20011227
BG 106287	A	20021031	BG 2002-106287	20020108
HK 1046141	A1	20060922	HK 2002-107761	20021025
US 20050234047	A1	20051020	US 2005-144103	20050603
US 7173054	B2	20070206		
US 20050239771	A1	20051027	US 2005-144126	20050603
US 7173034	B2	20070206		
US 20060154913	A1	20060713	US 2006-332557	20060112
US 7361657	B2	20080422		
US 20070021410	A1	20070125	US 2006-519719	20060911
PRIORITY APPLN. INFO.:			EP 1999-202087	A 19990628
			EP 2000-200452	A 20000211
			EP 2000-943841	A3 20000620
			WO 2000-EP5676	W 20000620
			US 2001-30202	A3 20011227
			US 2005-144103	A3 20050603
OTHER SOURCE(S):		MARPAT 134:86248		
GI				




- AB Use of title compds. [I; a1:a2a3:a4 = (substituted) CH:CHCH:CH, N:CHCH:CH, CH:N:CH:CH, CH:CHN:CH, CH:CHCH:N; Q = R2R4NAX1, R2R4NCOAX1, specified (heterocyclic) ring, etc.; A = alkylene; R2 = H, CHO, alkylcarbonyl, pyrrolidinyl, piperidinyl, homopiperidinyl, aminocycloalkyl, etc.; R4 = H, alkyl, aralkyl; G = bond, alkanediyl; R1 = (substituted) piperidinyl, piperazinyl, pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, etc.] for treatment of viral infection is claimed. Thus, 1,1-dimethylethyl 4-[[1-[[3,5-dihydro-3,3-dimethyl-9-(phenylmethoxy)-1H-1,3-dioxepino[5,6-c]pyridin-2-yl]methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinecarboxylate was refluxed 6 h in 10N HCl to give 4-[[1-[[3,5-dihydro-3,3-dimethyl-9-(phenylmethoxy)-1H-1,3-dioxepino[5,6-c]pyridin-2-yl]methyl]-1H-benzimidazol-2-yl]amino]piperidine. Tested I inhibited respiratory syncytial virus replication with IC50 = 0.00013-2.5119 μ M.
- IT 317846-37-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of benzimidazoles as respiratory syncytial virus replication

inhibitors)

RN 317846-37-0 CAPLUS

CN 3-Pyridinol, 2-[[2-[(3-amino-2-hydroxypropyl)amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




IT 317847-82-8

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of benzimidazoles as respiratory syncytial virus replication inhibitors)

RN 317847-82-8 CAPLUS

CN 3-Pyridinol, 2-[[2-[[3-[bis(phenylmethyl)amino]-2-(phenylmethoxy)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



REFERENCE COUNT:

17

THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT